5% ophthalmic solution. A post-marketing surveillance report of another ophthalmic solution used for the treatment of allergic conjunctivitis also demonstrated a higher incidence of ADRs, such as eye irritation, in females.[15] In the pre-marketing clinical find more trials of levofloxacin 0.5% ophthalmic solution, there were insufficient Smoothened Agonist data to determine the safety and efficacy of treatment in the pediatric setting, as only 16 children received levofloxacin ophthalmic solution (including ones who

received the 0.3% preparation). This study collected data on the use of levofloxacin in 1259 children and showed that levofloxacin 0.5% ophthalmic solution can be used safely in children. ADRs were reported in only 0.32% of the children, which was not higher than the rates reported in patients in the other age groups. This study also suggested that levofloxacin

0.5% ophthalmic solution is effective in everyday clinical practice. The clinical response rate of external ocular bacterial infections was high, with buy U0126 95.5% of all patients included in the efficacy analysis reporting a clinical response. In the subgroup analysis, the rate was lower in patients with dacryocystitis, elderly patients, patients with a long duration of illness, and relapsing cases. Dacryocystitis is typically a difficult disease to treat, and it appears that a longer duration of illness or a relapse of illness is also associated with lower efficacy. Furthermore, the low response rate observed in this study in elderly patients seems to be attributable to a high percentage of patients with dacryocystitis, cases with a long duration of illness, and relapsing cases. The clinical response observed with levofloxacin 0.5% ophthalmic solution was not reduced over time or when analyzed according to the type of ocular disease or the type Methocarbamol of bacterium involved. In parallel with this post-marketing surveillance, a drug sensitivity test was conducted to evaluate

the susceptibility of fresh clinically isolated bacterial strains (derived from patients with ocular infection) to levofloxacin and other drugs.[16–18] This test indicated that the bacterial strains associated with ocular infections did not tend to develop resistance to levofloxacin over time. However, it is important to monitor for the possible development of drug-resistant strains in the future, because bacterial strains with minimal inhibitory concentrations higher than 128 µg/mL were found among methicillin-resistant Staphylococcus aureus and Corynebacterium spp. soon after the marketing of levofloxacin 0.5% ophthalmic solution, and there was a report of cases developing infection with levofloxacin-resistant Corynebacterium spp. via the sutures.[19] Treatment with levofloxacin 0.5% ophthalmic solution was completed within 10 days in 50% of the cases.